Paul Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul Brown has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Jean-Philippe Brandel
2 shared publications- Maurizio Pocchiari
Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy
2 shared publications Takeshi Sato
2 shared publicationsAlfred E. Bacote
1 shared publicationAnna Ladogana
1 shared publication- Anne Balkema-Buschmann
Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany
1 shared publication
Latest Publications
- Open Access
- 19 December 2017
- Published by Springer Nature in Veterinary Research
- Vol. 48 (1) , 88
Detection of PrPBSE and prion infectivity in the ileal Peyer’s patch of young calves as early as 2 months after oral challenge with classical bovine spongiform encephalopathy
In classical bovine spongiform encephalopathy (C-BSE), an orally acquired prion disease of cattle, the ileal Peyer’s patch (IPP) represents the main entry port for the BSE agent. In earlier C-BSE pathogenesis studies, cattle at 4–6 months of age were orally challenged, while there are strong indications that the risk of infection is highest in young animals. In the present study, unweaned calves aged 4–6 weeks were orally challenged to determine the earliest time point at which newly formed PrPBSE and BSE infectivity are detectable in the IPP. For this purpose, calves were culled 1 week as well as 2, 4, 6 and 8 months post-infection (mpi) and IPPs were examined for BSE infectivity using a bovine PrP transgenic mouse bioassay, and for PrPBSE by immunohistochemistry (IHC) and protein misfolding cyclic amplification (PMCA) assays. For the first time, BSE prions were detected in the IPP as early as 2 mpi by transgenic mouse bioassay and PMCA and 4 mpi by IHC in the follicular dendritic cells (FDCs) of the IPP follicles. These data indicate that BSE prions propagate in the IPP of unweaned calves within 2 months of oral uptake of the agent.
- 19 December 2017
- Published by Springer Nature in Veterinary Research
- Vol. 48 (1) , 88
Open AccessDetection of PrPBSE and prion infectivity in the ileal Peyer’s patch of young calves as early as 2 months after oral challenge with classical bovine spongiform encephalopathy
In classical bovine spongiform encephalopathy (C-BSE), an orally acquired prion disease of cattle, the ileal Peyer’s patch (IPP) represents the main entry port for the BSE agent. In earlier C-BSE pathogenesis studies, cattle at 4–6 months of age were orally challenged, while there are strong indications that the risk of infection is highest in young animals. In the present study, unweaned calves aged 4–6 weeks were orally challenged to determine the earliest time point at which newly formed PrPBSE and BSE infectivity are detectable in the IPP. For this purpose, calves were culled 1 week as well as 2, 4, 6 and 8 months post-infection (mpi) and IPPs were examined for BSE infectivity using a bovine PrP transgenic mouse bioassay, and for PrPBSE by immunohistochemistry (IHC) and protein misfolding cyclic amplification (PMCA) assays. For the first time, BSE prions were detected in the IPP as early as 2 mpi by transgenic mouse bioassay and PMCA and 4 mpi by IHC in the follicular dendritic cells (FDCs) of the IPP follicles. These data indicate that BSE prions propagate in the IPP of unweaned calves within 2 months of oral uptake of the agent.
- 29 January 2016
- Published by Springer Nature
- p. 317-330
High-Pressure Inactivation of Transmissible Spongiform Encephalopathy Agents (Prions) in Processed Meats
- 29 January 2016
- Published by Springer Nature
- p. 317-330
High-Pressure Inactivation of Transmissible Spongiform Encephalopathy Agents (Prions) in Processed Meats
- 7 May 2015
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 36 (7) , 849
A New Practical Diagnostic Test for Creutzfeldt-Jakob Disease
- 7 May 2015
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 36 (7) , 849
A New Practical Diagnostic Test for Creutzfeldt-Jakob Disease
- Open Access
Evaluation of the Zoonotic Potential of Transmissible Mink Encephalopathy
Successful transmission of Transmissible Mink Encephalopathy (TME) to cattle supports the bovine hypothesis for the still controversial origin of TME outbreaks. Human and primate susceptibility to classical Bovine Spongiform Encephalopathy (c-BSE) and the transmissibility of L-type BSE to macaques indicate a low cattle-to-primate species barrier. We therefore evaluated the zoonotic potential of cattle-adapted TME. In less than two years, this strain induced in cynomolgus macaques a neurological disease similar to L-BSE but distinct from c-BSE. TME derived from another donor species (raccoon) induced a similar disease with even shorter incubation periods. L-BSE and cattle-adapted TME were also transmissible to transgenic mice expressing human prion protein (PrP). Secondary transmissions to transgenic mice expressing bovine PrP maintained the features of the three tested bovine strains (cattle TME, c-BSE and L-BSE) regardless of intermediate host. Thus, TME is the third animal prion strain transmissible to both macaques and humanized transgenic mice, suggesting zoonotic potentials that should be considered in the risk analysis of animal prion diseases for human health. Moreover, the similarities between TME and L-BSE are highly suggestive of a link between these strains, and therefore the possible presence of L-BSE for many decades prior to its identification in USA and Europe.
Open AccessEvaluation of the Zoonotic Potential of Transmissible Mink Encephalopathy
Successful transmission of Transmissible Mink Encephalopathy (TME) to cattle supports the bovine hypothesis for the still controversial origin of TME outbreaks. Human and primate susceptibility to classical Bovine Spongiform Encephalopathy (c-BSE) and the transmissibility of L-type BSE to macaques indicate a low cattle-to-primate species barrier. We therefore evaluated the zoonotic potential of cattle-adapted TME. In less than two years, this strain induced in cynomolgus macaques a neurological disease similar to L-BSE but distinct from c-BSE. TME derived from another donor species (raccoon) induced a similar disease with even shorter incubation periods. L-BSE and cattle-adapted TME were also transmissible to transgenic mice expressing human prion protein (PrP). Secondary transmissions to transgenic mice expressing bovine PrP maintained the features of the three tested bovine strains (cattle TME, c-BSE and L-BSE) regardless of intermediate host. Thus, TME is the third animal prion strain transmissible to both macaques and humanized transgenic mice, suggesting zoonotic potentials that should be considered in the risk analysis of animal prion diseases for human health. Moreover, the similarities between TME and L-BSE are highly suggestive of a link between these strains, and therefore the possible presence of L-BSE for many decades prior to its identification in USA and Europe.
- 15 October 2012
- Published by Springer Nature
- p. 1-19
Transmissible Spongiform Encephalopathy: From its Beginnings to Daniel Carlton Gajdusek
- 15 October 2012
- Published by Springer Nature
- p. 1-19
Transmissible Spongiform Encephalopathy: From its Beginnings to Daniel Carlton Gajdusek
- 15 October 2012
- Published by Springer Nature
- p. 73-88
Environmentally Acquired Transmissible Spongiform Encephalopathy
- 15 October 2012
- Published by Springer Nature
- p. 73-88
Environmentally Acquired Transmissible Spongiform Encephalopathy
- Top Cited PapersOpen Access
- 1 June 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (6) , 901-907
Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment
The era of iatrogenic Creutzfeldt-Jakob disease (CJD) has nearly closed; only occasional cases with exceptionally long incubation periods are still appearing. The principal sources of these outbreaks are contaminated growth hormone (226 cases) and dura mater grafts (228 cases) derived from human cadavers with undiagnosed CJD infections; a small number of additional cases are caused by neurosurgical instrument contamination, corneal grafts, gonadotrophic hormone, and secondary infection with variant CJD transmitted by transfusion of blood products. No new sources of disease have been identified, and current practices, which combine improved recognition of potentially infected persons with new disinfection methods for fragile surgical instruments and biological products, should continue to minimize the risk for iatrogenic disease until a blood screening test for the detection of preclinical infection is validated for human use.
- 1 June 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (6) , 901-907
Top Cited PapersOpen AccessIatrogenic Creutzfeldt-Jakob Disease, Final Assessment
The era of iatrogenic Creutzfeldt-Jakob disease (CJD) has nearly closed; only occasional cases with exceptionally long incubation periods are still appearing. The principal sources of these outbreaks are contaminated growth hormone (226 cases) and dura mater grafts (228 cases) derived from human cadavers with undiagnosed CJD infections; a small number of additional cases are caused by neurosurgical instrument contamination, corneal grafts, gonadotrophic hormone, and secondary infection with variant CJD transmitted by transfusion of blood products. No new sources of disease have been identified, and current practices, which combine improved recognition of potentially infected persons with new disinfection methods for fragile surgical instruments and biological products, should continue to minimize the risk for iatrogenic disease until a blood screening test for the detection of preclinical infection is validated for human use.
- 1 November 2009
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 8 (5) , 316-322
An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy
Efforts to treat transmissible spongiform encephalopathy (TSE) date back to the middle of the 20th century. Early studies were colored by the belief that TSE was caused by a ‘slow’ or ‘unconventional’ virus, and a variety of antiinfective agents, together with scores of drugs drawn at random from other categories, predictably failed to provide any benefit, apart from polyanionic compounds and polyene antibiotics that prolonged the incubation period of disease in experimental animals. With the discovery in the 1980s that TSE apparently results from the malformation of a normal host protein, attempts at treatment could at last be rationally focused, and can be broadly categorized as genetic, immunologic, and pharmacologic. Genetic ‘neutralization’ of the pathogen has shown excellent results in experimental animals but is unlikely to be useful until the same kind of engineering can be effectively applied to humans. Immunologic methods to accomplish the same result have also shown some success in animals, but forays into the pharmacologic realm have been generally disappointing. Most reported ‘successes’ have been limited to prolonged incubation periods, and even then only when the treatment was begun at or near the time of infection, which is not known in sporadic or familial human disease. However, a few methods using the more rigorous model of treatment nearer the onset of symptomatic disease have begun to yield promising results that, if coupled with a practical screening test for pre-clinical infection, would be the optimal strategy for prevention or cure.
- 1 November 2009
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 8 (5) , 316-322
An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy
Efforts to treat transmissible spongiform encephalopathy (TSE) date back to the middle of the 20th century. Early studies were colored by the belief that TSE was caused by a ‘slow’ or ‘unconventional’ virus, and a variety of antiinfective agents, together with scores of drugs drawn at random from other categories, predictably failed to provide any benefit, apart from polyanionic compounds and polyene antibiotics that prolonged the incubation period of disease in experimental animals. With the discovery in the 1980s that TSE apparently results from the malformation of a normal host protein, attempts at treatment could at last be rationally focused, and can be broadly categorized as genetic, immunologic, and pharmacologic. Genetic ‘neutralization’ of the pathogen has shown excellent results in experimental animals but is unlikely to be useful until the same kind of engineering can be effectively applied to humans. Immunologic methods to accomplish the same result have also shown some success in animals, but forays into the pharmacologic realm have been generally disappointing. Most reported ‘successes’ have been limited to prolonged incubation periods, and even then only when the treatment was begun at or near the time of infection, which is not known in sporadic or familial human disease. However, a few methods using the more rigorous model of treatment nearer the onset of symptomatic disease have begun to yield promising results that, if coupled with a practical screening test for pre-clinical infection, would be the optimal strategy for prevention or cure.
- 26 February 2008
- Published by Wolters Kluwer Health in Neurology
- Vol. 70 (9) , 713-722
Transmissible spongiform encephalopathy in the 21st century
- 26 February 2008
- Published by Wolters Kluwer Health in Neurology
- Vol. 70 (9) , 713-722
Transmissible spongiform encephalopathy in the 21st century
- 7 December 2007
- Published by Wiley in Haemophilia
- Vol. 13 (s5) , 33-40
Creutzfeldt‐Jakob disease: reflections on the risk from blood product therapy
Abstract Creutzfeldt‐Jakob disease (CJD) was first described as a clinical entity in the 1920s, first transmitted experimentally in 1968, and first transmitted iatrogenically in 1972 (corneal transplant). Numerous experimental studies in rodents, sheep and primates have since revealed very low levels of infectivity in blood (about 1/100 000th the level in brain tissue) that can appear as early as half‐way through the incubation period, with 5–10 fold higher concentrations in leucocytes than plasma. Transfused blood from individuals incubating the variant form of CJD has transmitted infection to four recipients in the United Kingdom, and several dozen other recipients remain at risk. Plasma and plasma proteins have not been implicated in any transmissions, and no instance of transmission from the blood of individuals incubating other forms of CJD has been recognized. Strategies to prevent iatrogenic transmissions include low‐risk sourcing, leucodepletion, and a variety of infectivity‐reducing plasma processing steps; screening tests to detect infection in preclinical donors are under development.
- 7 December 2007
- Published by Wiley in Haemophilia
- Vol. 13 (s5) , 33-40
Creutzfeldt‐Jakob disease: reflections on the risk from blood product therapy
Abstract Creutzfeldt‐Jakob disease (CJD) was first described as a clinical entity in the 1920s, first transmitted experimentally in 1968, and first transmitted iatrogenically in 1972 (corneal transplant). Numerous experimental studies in rodents, sheep and primates have since revealed very low levels of infectivity in blood (about 1/100 000th the level in brain tissue) that can appear as early as half‐way through the incubation period, with 5–10 fold higher concentrations in leucocytes than plasma. Transfused blood from individuals incubating the variant form of CJD has transmitted infection to four recipients in the United Kingdom, and several dozen other recipients remain at risk. Plasma and plasma proteins have not been implicated in any transmissions, and no instance of transmission from the blood of individuals incubating other forms of CJD has been recognized. Strategies to prevent iatrogenic transmissions include low‐risk sourcing, leucodepletion, and a variety of infectivity‐reducing plasma processing steps; screening tests to detect infection in preclinical donors are under development.